Simponi: new addition to TNF inhibitor class

Simponi (golimumab) is a new option for the second-line treatment of TNF-mediated joint diseases.

PHARMACOLOGY

Simponi (golimumab) is a monoclonal antibody against tumour necrosis factor (TNF).1 It is administered monthly by subcutaneous injection.

CLINICAL STUDIES

Simponi is licensed for three indications:

  • In combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis when the response to DMARDs (including methotrexate) has been inadequate.

Two studies examined the efficacy of golimumab in this setting. GO-FORWARD2 enrolled 444 patients who had failed to respond adequately to methotrexate; GO-AFTER3 recruited 461 patients previously treated with another TNF inhibitor. In both studies, participants continued their DMARD treatment (oral methotrexate in GO-FORWARD).

In GO-FORWARD, 55% of the patients treated with 50mg golimumab achieved a 20% or higher American College of Rheumatology criteria for assessment of rheumatoid arthritis (ACR20) response by 14 weeks, compared with 33% of those who received placebo (p=0.001). The corresponding response rates in GO-AFTER were 35% and 18%, respectively (p=0.0006).

  • Active and progressive psoriatic arthritis when the response to DMARDs has been inadequate

GO-REVEAL4 tested golimumab in 405 patients fitting this description. At week 14, 51% of the patients receiving 50mg dose of the antibody and 9% of patients receiving placebo had achieved an ACR20 response (p<0.001).

  • Severe active ankylosing spondylitis when the response to conventional therapy has been inadequate

GO-RAISE5 enrolled 356 patients meeting this criterion. After 14 weeks, 59% of patients in the golimumab 50mg group had achieved at least 20% improvement in the Assessment in AS International Working Group Criteria (ASAS20) response compared with 22% of patients in the placebo group (p<0.001).

View Simponi drug record

REFERENCES

  1. Simponi Summary of Product Characteristics, July 2010.
  2. Keystone E et al. Ann Rheum Dis 2009; 68: 789-96.
  3. Smolen JS et al. Lancet 2009; 374: 210-21.
  4. Kavanaugh A et al. Arthritis Rheum 2009; 60: 976-86.
  5. Inman RD et al. Arthritis Rheum 2008; 58: 3402-12.
Further information: Merck Sharp & Dohme

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases